(function(){var loadHandler=window['sl_{960D82CC-96CE-4808-B775-17F97F35928F}'];loadHandler&&loadHandler(16, '<div id="spr0_1774763"><div id="spr1_1774763" class="kern"><img id="img0_1774763" src="data/img6.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_1774763" class="kern"><div id="spr3_1774763" style="left:5.67px;top:37.533px;"><div style="width:0px;"><span id="txt0_1774763" class="relpos" style="left:10.448px;top:5.198px;">A combination therapy of GEM with immunotherapy</span></div><div style="width:0px;"><span id="txt1_1774763" class="relpos" style="left:19.868px;top:41.198px;">for unresectable locally advanced pancreatic cancer.</span></div></div><div id="spr4_1774763" style="left:384.2px;top:133.922px;"><div style="width:0px;"><span id="txt2_1774763" class="relpos" style="left:25.53px;top:4.452px;">Hirooka Y, et al. Pancreas 2009 ;38:e69-74.</span></div></div><div id="spr5_1774763" style="left:42.484px;top:179.281px;"><div style="width:0px;"><span id="txt3_1774763" class="nokern relpos" style="left:7.2px;top:5.067px;"></span><span id="txt4_1774763" class="relpos" style="left:16.722px;top:4.772px;">5 patients were enrolled.</span></div><div style="width:0px;"><span id="txt5_1774763" class="nokern relpos" style="left:7.2px;top:57.867px;"></span><span id="txt6_1774763" class="relpos" style="left:16.722px;top:57.572px;">Intravenous GEM administration at 1000 mg/m</span><span id="txt7_1774763" class="relpos" style="left:16.717px;top:57.662px;">2</span><span id="txt8_1774763" class="relpos" style="left:16.712px;top:57.572px;"> (day 1) and the</span></div><div style="width:0px;"><span id="txt9_1774763" class="relpos" style="left:34.2px;top:83.972px;">EUS-FNI DCs into a tumor, followed by intravenous infusion of</span></div><div style="width:0px;"><span id="txt10_1774763" class="relpos" style="left:34.2px;top:110.372px;">lymphokine-activated killer cells (day 4), at 2-week intervals.</span></div><div style="width:0px;"><span id="txt11_1774763" class="nokern relpos" style="left:7.2px;top:163.467px;"></span><span id="txt12_1774763" class="relpos" style="left:16.722px;top:163.172px;">3 of the 5 patients demonstrated effective responses to this clinical</span></div><div style="width:0px;"><span id="txt13_1774763" class="relpos" style="left:34.2px;top:189.572px;">trial; 1 had partial remission and 2 had long stable disease more than</span></div><div style="width:0px;"><span id="txt14_1774763" class="relpos" style="left:34.2px;top:215.972px;">6 months.</span></div><div style="width:0px;"><span id="txt15_1774763" class="nokern relpos" style="left:7.2px;top:269.067px;"></span><span id="txt16_1774763" class="relpos" style="left:16.722px;top:268.772px;">No serious treatment-related adverse events were observed.</span></div></div></div></div>');})();